DGAP-Adhoc

GSK and Genmab Announce Submission to US Regulatory Authorities for Arzerra(r) (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL) - Seite 2

antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab's validated and next generation
antibody technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and technologies is a
key focus of Genmab's strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.

Genmab Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: [phone]; M: [phone]; E: [e-mail]

GlaxoSmithKline Enquiries:

UK Media enquiries:
David Mawdsley [phone] (London)
Catherine Hartley [phone] (London)

US Media enquiries:
Bernadette King [phone] (Philadelphia)
Anna Padula [phone] (Philadelphia)
Stephen Rea [phone] (Philadelphia)
Melinda Stubbee [phone] (North Carolina)
Karen Collins [phone] (North Carolina)

Analyst/Investor enquiries:
Ziba Shamsi + 44 (0) 20 8047 3289 (London)
Lucy Budd [phone] (London)
Gary Davies + 44 (0) 20 8047 5503 (London)
James Dodwell + 44 (0) 20 8047 2406 (London)
Tom Curry + 1 215 751 5419 (Philadelphia)
Jeff McLaughlin + 1 215 751 7002 (Philadelphia)


Forward Looking Statement for Genmab
This Company Announcement contains forward looking statements. The words
'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain